AstraZeneca Doesn’t Believe In Booster Dose, Says Ceo Pascal Soriot

0
278
AstraZeneca Doesn’t Believe In Booster Dose, Says Ceo Pascal Soriot

Amidst the debates, whether a booster dose is necessary for people, AstraZeneca says that it is not sure if the third dose of its company’s vaccine will be necessary, said the CEO to CNBC on Thursday. 

Pascal Soriot said to CNBC’s Squawk Box Europe that the company is yet to have a precise answer on third dose importance in protection against the COVID-19 pandemic. Soriot said that there are two sides to this immunity, antibodies decrease as time passes and the second side to it is the T-cells. They prevent people from severe disease and provide durability. With the use of present advanced technology, the production of T-cells is very high. The company is hoping that they can have a vaccine with long-lasting durability that can protect people for longer periods of time. So, they are not yet sure if booster doses are necessary, coming time will tell. 

AstraZeneca Doesn’t Believe In Booster Dose, Says Ceo Pascal Soriot

T-cells are similar to white blood cells which function as defenders of the body against the virus. Antibodies may forbid viruses from invading the cells, however, they are not as long-lasting as T-cells. The only way to check whether a third dose will be required to prevent the infection is after examining the vaccine’s efficacy wearing off. 

AstraZeneca Doesn’t Believe In Booster Dose, Says Ceo Pascal Soriot

Albert Bourla, CEO of Pfizer said on Wednesday that their company is very confident that their vaccine’s third dose will provide high immunity to people against the most contagious delta variant. This statement came after one research said that Pfizer-BioNTech’s vaccine efficacy has decreased by 6% every two months. The vaccine proved to be the most effective between one week to two months after its first shot. After four to six months, the effectiveness further decreased to 84%. 

The company’s total revenue has increased to $1.2 billion from its COVID-19 vaccines, during the first six months. The vaccine sales revenue helped the Anglo-Swedish pharmaceutical giant, whose income increased by 23% in six months to $15.5 billion, as announced by AstraZeneca

Experts are worried that the vaccines for COVID-19 do not offer the necessary immunity against new variants. Evidence suggests that vaccinated people are at low risk of catching the infection, and even if they do, it would not need people to get admitted to hospitals and get severely ill. However, experts are worried about the newly found delta variant. 

Research conducted concluded that more than 95% of people who took both vaccination shots of the Pfizer-BioTech or Oxford-AstraZeneca COVID-19 proved to be weaker against the Delta variant than other strains. People who got one shot of the vaccine were even more at risk than those who were fully vaccinated with two doses. It suggests that a single dose of vaccine can no longer even remotely protect people against the Delta variant.

In the span of six months, the effectiveness of the Delta variant fell to just 64%. However, two vaccine shots are effective in 93% of cases to prevent serious illness. This helps the immune system to slowly build sustainability and next time an infection enters, it can react quickly. Most of the boosters are the same as the previous doses, while some are modified to enhance the

According to data collected by Bloomberg, around 4 billion COVID-19 vaccine shots have been given throughout the world. Our World in Data says that the vaccination programs have been started in 214 countries, out of which a majority have Oxford-AstraZeneca approved vaccines for use.

The debates on whether the need will arise will probably continue for some time. But as advised by experts, medical officials and those sitting on higher levels of administration, the only safe escape from the pandemic is only through increased vaccination rates.

LEAVE A REPLY

Please enter your comment!
Please enter your name here